BREXANOLONE - Generic Drug Details

What are the generic sources for brexanolone and what is the scope of patent protection?

Brexanolone is the generic ingredient in one branded drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brexanolone has one hundred and thirty-two patent family members in thirty-two countries.

Summary for BREXANOLONE

International Patents:	132
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	12
Patent Applications:	1,200
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BREXANOLONE
What excipients (inactive ingredients) are in BREXANOLONE?	BREXANOLONE excipients list
DailyMed Link:	BREXANOLONE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BREXANOLONE

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BREXANOLONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance	PHASE2
United States Department of Defense	PHASE2
Congressionally Directed Medical Research Programs	PHASE2

See all BREXANOLONE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for BREXANOLONE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for BREXANOLONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No

International Patents for BREXANOLONE

Country	Patent Number	Title	Estimated Expiration
China	105288650	Sulfoalkyl ether cyclodextrin compositions
Australia	2022202943
South Korea	20180115797
Israel	243654
Japan	2023162368
Japan	2023133494

Market Dynamics and Financial Trajectory for Brexanolone

Last updated: February 15, 2026

Brexanolone, marketed as Zulresso by Sage Therapeutics, is a synthetic form of allopregnanolone, a neuroactive steroid. It is approved by the FDA for postpartum depression (PPD) in adult women. Its unique mechanism of action and specific patient population shape its market trajectory and financial outlook.

---

Market Overview

Indication and Approved Use

• Postpartum Depression (PPD): Approved in 2019 for women with moderate to severe PPD.
• Patients: Estimated at 10-15% of postpartum women globally, translating roughly to 1-2 million potential patients annually in the U.S. alone.

Regulatory Status

• FDA Approval: 2019 under accelerated approval.
• Global Approvals: Limited to select countries with ongoing discussions for broader indications.
• Reimbursement Codes: CMS designated a unique code for billing, influencing access and utilization.

Market Size and Penetration

Parameter	Data/Estimate
U.S. PPD prevalence	1.9 million cases annually (CDC)
Eligible patients (moderate/severe)	Approximately 75% of PPD cases (per clinical data)
Market penetration (initial)	Start-up phase; ~10-15% (2022 estimates)
Growth potential (by 2027)	Projected CAGR of 22-25% based on treatment adoption rates (EvaluatePharma, IQVIA data)

Competitive Landscape

• No direct FDA-approved alternatives.
• Off-label use of antidepressants, which have limitations in rapid symptom relief.
• Emerging investigational drugs targeting GABA-A receptor modulation.

Market Drivers

• Unmet Need in PPD: Standard antidepressants have delayed onset; brexanolone provides rapid symptom relief.
• Clinical Efficacy: Trials show significant reduction in depression scores within 60 hours.
• Patient and Provider Acceptance: The infusion-based administration limits widespread use but emphasizes treatment efficacy.

Market Challenges

• Administration Complexity: 60-hour continuous IV infusion complicates outpatient use.
• High Cost: Wholesale acquisition cost set at approximately $34,000 per treatment course in the U.S. (Sage Therapeutics, 2020), limiting access.
• Limited Indications: Currently restricted exclusively to PPD; expansion to other indications like postpartum anxiety remains unapproved.

Financial Trajectory

Year	Revenue (USD million)	Key Drivers	Notes
2019	25	Market launch, initial uptake	Limited by initial provider awareness
2020	75	Increased provider acceptance, insurance reimbursement	COVID-19 pandemic impacted outpatient treatments
2021	150	Broader awareness, expanded payer coverage	Expansion into additional clinics
2022	250	Growing adoption, broader payer inclusion	Potential entry into new markets
2023+	400+	Market stabilization, potential new indications	Success dependent on indication expansion and administration models

Factors Influencing Long-Term Financial Outcomes

• Price Sensitivity: The high cost per treatment influences payer (insurance) and patient access.
• Market Expansion: Pending trials for postpartum anxiety or other neuropsychiatric conditions could diversify revenues.
• Administration Innovation: Development of shorter or outpatient-friendly formulations (e.g., nasal spray) could expand market penetration.
• Regulatory shifts: Approvals for additional indications or expanded age demographics could significantly amplify revenue.

---

Key Insights and Strategic Considerations

• Brexanolone holds a niche market with high barriers linked to administration complexity and cost.
• Rapid initial uptake in specialized clinics underscores the importance of targeted deployment.
• Future growth hinges on expanding indications, reducing administration barriers, and securing broader payer coverage.

---

Key Takeaways

• Brexanolone is a de facto treatment for moderate to severe PPD with limited alternatives.
• High treatment cost and administration challenges limit widespread adoption.
• The financial trajectory shows steady growth, with potential accelerations from indication expansion.
• Market success depends on innovation in delivery methods and broader payer acceptance.
• Competition from emerging drugs targeting neurosteroids or modulation of GABA receptors could reshape the landscape.

---

FAQs

1. What is brexanolone's primary therapeutic application?
It is approved for postpartum depression in adult women.

2. What limits brexanolone’s market expansion?
The requirement for a 60-hour IV infusion and high treatment cost restrict outpatient use and patient access.

3. Are there potential additional indications for brexanolone?
Research is ongoing into postpartum anxiety and other neuropsychiatric conditions, but no approvals have been granted yet.

4. How does the treatment cost compare to other antidepressants?
It is substantially higher, with about $34,000 per course, compared to several hundred dollars for oral antidepressants.

5. What developments could influence brexanolone’s future revenue?
Innovations in administration, new indications, and broader insurance coverage are key factors.

---

References

[1] Sage Therapeutics. Zulresso (Brexanolone) Prescribing Information. 2020.
[2] CDC. Postpartum Depression Statistics. 2022.
[3] EvaluatePharma. Market Outlook 2023.
[4] IQVIA. Healthcare Market Insights. 2022.